Medicine
Anzupgo 2% cream
Anzupgo 2% cream is a prescription medicine containing Delgocitinib for topical use, marketed by LEO Pharma, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Do not freeze. Store ANZUPGO at 20ºC to 25ºC (68ºF to 77ºF), excursions…
Key facts
- Active ingredient (INN)
- Delgocitinib
- Brand
- Anzupgo
- Strength
- 2%
- Dosage form
- Cream
- Route
- Topical
- Packs
- 1 tube
- Marketing authorisation holder
- LEO Pharma
- Manufacturer
- LEO Pharma
- Origin register
- US FDA, United States
- Storage
- Do not freeze. Store ANZUPGO at 20ºC to 25ºC (68ºF to 77ºF), excursions permitted from 15°C to 30°C (59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- D11AH11 Delgocitinib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 24 July 2025
- Identifiers
- RxCUI 2721167, 2721172DailyMed set ID a59bf36e-6f04-4b47-b385-8040c95f040cNDC 50222-280Application NDA219155
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 tube in 1 carton / 30 g in 1 tube | 50222-280-30 | LEO Pharma | 24 July 2025 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Delgocitinib is a janus kinase inhibitor indicated for the topical treatment of moderate to severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable. MedsAcross supplies Delgocitinib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about DelgocitinibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Anzupgo prescribing information (LEO Pharma) · U.S. National Library of Medicine, DailyMed
- Anzupgo: European public assessment report (EPAR) · European Medicines Agency
Need Anzupgo 2% cream for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.